Hosted on MSN12mon
Assembly Bio to launch four infectious disease trials in 2024In H1, the company hopes to initiate a first-in-human (FIH) trial of its candidate ABI-5366, a helicase-primase inhibitor targeting patients with HSV2, specifically recurrent genital herpes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback